The Ras-association domain family (RASSF) members and their role in human tumourigenesis

作者: Louise van der Weyden , David J. Adams

DOI: 10.1016/J.BBCAN.2007.06.003

关键词:

摘要: Ras proteins play a direct causal role in human cancer with activating mutations occurring ∼ 30% of tumours. effectors also contribute to cancer, as occur effectors, notably B-Raf and PI3-K, drugs blocking elements these pathways are clinical development. In 2000, new effector was identified, RAS-association domain family 1 (RASSF1), expression the RASSF1A isoform this gene is silenced tumours by methylation its promoter. Since reversible demethylating agents currently being used trials, detection silencing promoter hypermethylation has potential uses diagnosis, prognosis treatment. belongs RAS which there 8 members (RASSF1–8). RASSF1–6 each contain variable N-terminal segment followed Ras-association (RA) Ral-GDS/AF6 type, specialised coiled-coil structure known SARAH extending C-terminus. RASSF7–8 an RA Members RASSF thought function tumour suppressors regulating cell cycle apoptosis. This review will summarise our current knowledge member particular what they tumourigenesis, special focus on RASSF1A, whose one most frequent alterations found

参考文章(209)
P. Rabbitts, R. Rudd, G. Sinha, P. Hasleton, P. Ganly, N. M. Bleehen, V. Sundaresan, p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus Oncogene. ,vol. 7, pp. 1989- 1997 ,(1992)
Sabine Zöchbauer-Müller, Arthur Sagalowsky, John D. Minna, Bogdan Czerniak, Funda Vakar-Lopez, Adi F. Gazdar, Shinichi Toyooka, Arvind K. Virmani, Alfredo J. Farinas, Kiyomi O. Toyooka, Kenichi Harada, Riichiroh Maruyama, Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features Cancer Research. ,vol. 61, pp. 8659- 8663 ,(2001)
Reinhard Dammann, Chun Li, Jung-Hoon Yoon, Philip L. Chin, Steven Bates, Gerd P. Pfeifer, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics. ,vol. 25, pp. 315- 319 ,(2000) , 10.1038/77083
Gary W. Reuther, Janice E. Buss, Lawrence A. Quilliam, Geoffrey J. Clark, Channing J. Der, Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences. Methods in Enzymology. ,vol. 327, pp. 331- 350 ,(2000) , 10.1016/S0076-6879(00)27288-1
Sung-Goo Chang, Jin Il Kim, Choong-Hyun Lee, Sung-Gil Chi, Sun-Ju Lee, Hee-Yul Kim, Do-Sun Byun, Min-Goo Lee, Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Research. ,vol. 61, pp. 6688- 6692 ,(2001)
Dammann R, Strunnikova M, Pfeifer Gp, Rastetter M, Seidel C, Schagdarsurengin U, Baier K, The tumor suppressor RASSF1A in human carcinogenesis: an update. Histology and Histopathology. ,vol. 20, pp. 645- 663 ,(2005) , 10.14670/HH-20.645
Joseph Avruch, Maria Praskova, Sara Ortiz‐Vega, Matthew Liu, Xian‐Feng Zhang, Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods in Enzymology. ,vol. 407, pp. 290- 310 ,(2006) , 10.1016/S0076-6879(05)07025-4
Paula Lázcoz, Jorge Muñoz, Manuel Nistal, Ángel Pestaña, Ignacio Encío, Javier S Castresana, Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma BMC Cancer. ,vol. 6, pp. 254- 254 ,(2006) , 10.1186/1471-2407-6-254
Klaas Kok, Susan L. Naylor, Charles H.C.M. Buys, Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes Advances in Cancer Research. ,vol. 71, pp. 27- 92 ,(1997) , 10.1016/S0065-230X(08)60096-2
Eugene Zabarovsky, John D. Minna, W. Marston Linehan, Youfeng Yang, Igor Kuzmin, Michael I. Lerman, Laura Geil, John W. Gillespie, Fuh Mei Duh, Johng S. Rhim, Koen Dreijerink, Michael R. Emmert-Buck, Alexei Protopopov, Cathy D. Vocke, The RASSF1A Tumor Suppressor Gene Is Inactivated in Prostate Tumors and Suppresses Growth of Prostate Carcinoma Cells Cancer Research. ,vol. 62, pp. 3498- 3502 ,(2002)